MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion
| dc.contributor.author | Verghese, Eldo T. | |
| dc.contributor.author | Drury, Ruth | |
| dc.contributor.author | Green, Caroline A. | |
| dc.contributor.author | Holliday, Deborah L. | |
| dc.contributor.author | Lu, Xiaomei | |
| dc.contributor.author | Nash, Claire | |
| dc.contributor.author | Speirs, Valerie | |
| dc.contributor.author | Thorne, James L. | |
| dc.contributor.author | Thygesen, Helene H. | |
| dc.contributor.author | Zougman, Alexandre | |
| dc.contributor.author | Hull, Mark A. | |
| dc.contributor.author | Hanby, Andrew M. | |
| dc.contributor.author | Hughes, Thomas A. | |
| dc.date.accessioned | 2018-07-24T09:22:11Z | |
| dc.date.available | 2018-07-24T09:22:11Z | |
| dc.date.issued | 2013-11 | |
| dc.description | This work was supported by the Medical Research Council (ETV), Breast Cancer Campaign (ETV, TAH, VS), Breast Cancer Research Action Group (TAH), Cancer Research UK (HHT, ref C37059/A11941), The Pathological Society UK (ETV), Yorkshire Cancer Research (LMD platform), University of Leeds (CG), and Leeds Institute of Molecular Medicine (CN). We thank Georgia Mavria (University of Leeds), Sean Lawler (Harvard Medical School), and Eric Sahai and Steven Hooper (CR‐UK LRI) for technical advice. | en | 
| dc.description.status | Peer reviewed | en | 
| dc.format.extent | 12 | |
| dc.format.extent | 2514953 | |
| dc.identifier | 129548012 | |
| dc.identifier | 6b1de514-9aee-4260-af06-d61f2a042229 | |
| dc.identifier | 23939832 | |
| dc.identifier | 84885406105 | |
| dc.identifier.citation | Verghese, E T, Drury, R, Green, C A, Holliday, D L, Lu, X, Nash, C, Speirs, V, Thorne, J L, Thygesen, H H, Zougman, A, Hull, M A, Hanby, A M & Hughes, T A 2013, 'MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion', The Journal of pathology, vol. 231, no. 3, pp. 388-399. https://doi.org/10.1002/path.4248 | en | 
| dc.identifier.doi | 10.1002/path.4248 | |
| dc.identifier.iss | 3 | en | 
| dc.identifier.issn | 0022-3417 | |
| dc.identifier.other | PubMedCentral: PMC4030585 | |
| dc.identifier.other | ORCID: /0000-0002-0602-4666/work/72631307 | |
| dc.identifier.uri | http://hdl.handle.net/2164/10787 | |
| dc.identifier.vol | 231 | en | 
| dc.language.iso | eng | |
| dc.relation.ispartof | The Journal of pathology | en | 
| dc.subject | SDG 3 - Good Health and Well-being | en | 
| dc.subject | fibroblast | en | 
| dc.subject | stroma | en | 
| dc.subject | microRNA | en | 
| dc.subject | tumour microenvironment | en | 
| dc.subject | microRNA-26b | en | 
| dc.subject | RC0254 Neoplasms. Tumors. Oncology (including Cancer) | en | 
| dc.subject | Medical Research Council (MRC) | en | 
| dc.subject | Cancer Research UK | en | 
| dc.subject | C37059/A11941 | en | 
| dc.subject.lcc | RC0254 | en | 
| dc.title | MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion | en | 
| dc.type | Journal article | en | 
